01 Shift toward Personalized Cancer Biological Therapies The cancer biological therapy market analysis shows a shift toward personalized cancer biological therapies that are selected according to patient-specific biomarkers, tumor characteristics, and molecular profiles. Advances in biomarker testing and molecular diagnostics are supporting the identification of biological therapies suited to individual patient profiles.
02 Growth of Combination Immunotherapy Approaches The cancer biological therapy market is witnessing growth in combination immunotherapy approaches that use multiple immune-based therapies or combine immunotherapy with other cancer treatments. These approaches are being developed to target different mechanisms involved in tumor growth and immune response. This development is expanding treatment strategies for cancers with complex biological characteristics.Supply chain disruptions are expected to have a high impact on the cancer biological therapy market share due to dependence on biologic drug ingredients, cell culture materials, specialized manufacturing facilities, cold chain storage, and temperature-controlled pharmaceutical distribution networks. The market is expected to follow a stair-step recovery, as shortages of biologic manufacturing inputs, production delays, cold chain constraints, and transportation disruptions can affect therapy availability in phases before manufacturing and distribution capacity stabilize. The market is expected to grow at a CAGR of 6.58%, but supply chain constraints could approximately lower this by 1.0 percentage point, resulting in short-term growth of around 5.58%. As supply conditions normalize through improved availability of biologic manufacturing inputs, stable production capacity, reliable cold chain infrastructure, and smoother pharmaceutical distribution, cancer biological therapy market growth is expected to gradually return to 6.58%.The cancer biological therapy market forecasts strategic investment activity driven by antibody-based therapies, immunocytokines, antibody drug conjugates, targeted immunotherapies, and clinical development of innovative treatments across multiple cancer types.
03 Key Investment and Funding Activities in Cancer Biological Therapy Market, 2026 Company Value (USD) Details Summit Therapeutics USD 2 Billion In September 2026, AstraZeneca announced a USD 2 billion equity investment in Summit Therapeutics to accelerate development of ivonescimab and its combination with antibody drug conjugates across cancer types. CellCentric USD 220 Million In May 2026, CellCentric completed a USD 220 million Series D financing to advance pivotal trials of inobrodib for multiple myeloma.
01 Preference for Bispecific Antibody Therapies and Expansion of Targeted Cancer Therapies Drives Market The growth of bispecific antibody therapies is increasing demand for biological treatments that can target two specific proteins or cells at the same time. These therapies can help connect immune cells with cancer cells or block multiple disease pathways. Their development across different cancer types is expanding treatment options and supporting growth of the cancer biological therapy market.The expansion of targeted cancer therapies is driving demand for biological treatments designed to act on specific molecules involved in cancer growth. These therapies can offer more selective treatment approaches based on tumor characteristics and biomarkers.
01 Risk of Adverse Effects and High Cost of Cancer Biological Treatment Restrains Market Expansion The risk of adverse effects associated with biological therapies can limit their use in cancer treatment. Therapies such as immunotherapies, monoclonal antibodies, and other biologic treatments may cause immune-related reactions, infusion-related effects, or other treatment complications. These concerns can affect treatment decisions and restrain market growth.The high cost of cancer biological therapies can create affordability challenges for patients and healthcare providers. Biological therapies often involve complex research, specialized manufacturing, storage, and administration requirements, which can increase treatment expenses.
01 Expansion of Biological Therapies in Precision Cancer Care and Combination Cancer Treatment Offers Growth Opportunities The use of targeted cancer treatments is creating opportunities for biological therapy providers to serve oncology centers and pharmaceutical companies. Monoclonal antibodies, cytokines, and other biologics can address specific cancer targets. Revenue can be generated through therapy sales, licensing, and treatment partnerships, contributing to cancer biological therapy market growth.The use of combination approaches is creating opportunities for biological therapy providers to develop treatments used alongside other cancer therapies. Combination regimens can help address different disease pathways within cancer treatment. Revenue can be generated through therapy sales, clinical partnerships, and licensing agreements, supporting market growth.
01 Complex Biomarker Testing and Long-Term Treatment Monitoring Challenges Market Growth Cancer biological therapies often depend on identifying patients whose tumors have specific biomarkers or molecular characteristics. Differences in testing availability and patient biology can make treatment selection more complex. These challenges can limit eligible patient pools and make it harder for companies to expand targeted therapies across cancer types.Biological therapies often require ongoing monitoring to assess treatment response, immune reactions, and changes in disease status. Frequent clinical assessments can increase healthcare resource requirements and make treatment management more complex.